Anson Funds Management LP Invests $1.76 Million in Liquidia Co. (NASDAQ:LQDA)

Anson Funds Management LP purchased a new stake in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 176,403 shares of the company's stock, valued at approximately $1,764,000. Anson Funds Management LP owned approximately 0.23% of Liquidia as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Whitcomb & Hess Inc. increased its position in shares of Liquidia by 10.2% during the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company's stock valued at $116,000 after acquiring an additional 1,074 shares in the last quarter. Arizona State Retirement System grew its position in Liquidia by 10.7% in the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company's stock worth $166,000 after purchasing an additional 1,341 shares during the period. Quest Partners LLC bought a new stake in Liquidia in the 2nd quarter worth approximately $27,000. Price T Rowe Associates Inc. MD grew its position in Liquidia by 26.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,341 shares of the company's stock worth $212,000 after purchasing an additional 2,999 shares during the period. Finally, Profund Advisors LLC grew its position in Liquidia by 31.6% in the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company's stock worth $173,000 after purchasing an additional 3,466 shares during the period. Institutional investors own 64.54% of the company's stock.

Liquidia Trading Down 4.1 %

Shares of LQDA traded down $0.47 during trading hours on Friday, reaching $11.01. 1,017,120 shares of the stock traded hands, compared to its average volume of 805,838. Liquidia Co. has a 52-week low of $6.86 and a 52-week high of $16.99. The company's 50-day moving average price is $10.84 and its two-hundred day moving average price is $11.29. The company has a market cap of $931.89 million, a P/E ratio of -6.75 and a beta of 0.22.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on LQDA. HC Wainwright reiterated a "buy" rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday, November 14th. Needham & Company LLC reiterated a "buy" rating and set a $19.00 price target on shares of Liquidia in a research note on Thursday, November 14th. Bank of America dropped their price target on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Tuesday, August 20th. Raymond James upgraded shares of Liquidia from an "outperform" rating to a "strong-buy" rating in a research note on Monday, August 19th. Finally, Scotiabank began coverage on shares of Liquidia in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $24.00.

Insider Activity at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 2,526 shares of Liquidia stock in a transaction on Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the sale, the insider now directly owns 204,857 shares in the company, valued at approximately $2,292,349.83. The trade was a 1.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the sale, the chief executive officer now owns 812,193 shares in the company, valued at approximately $9,023,464.23. This represents a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,007 shares of company stock worth $245,780. 30.10% of the stock is owned by corporate insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).